New Explanation for Why Airways Close in Asthma Holds Promise for Future Class of Drugs

Article ID: 688756

Released: 31-Jan-2018 2:05 PM EST

Source Newsroom: The Rockefeller University Press

Newswise — Houston Methodist researchers have a new explanation for what causes the lungs’ airways to close during asthma attacks. The researchers who published the study in the Feb. 5 issue of the Journal of Experimental Medicine note that the discovery holds promise for developing a new class of drugs different from the steroids currently used to treat asthma.

According to the World Health Organization, 235 million people currently suffer from asthma, and it is a common disease among children. One of the key features of asthma is an overproduction of a highly sticky protein secreted by the mucous membranes of airways in the lungs, called mucin, which leads to plugging up the small airways and stopping air from traveling in and out of them. This leaves those with the condition out of breath and, oftentimes, causes them to gasp for air.

Led by Xian C. Li, M.D., Ph.D., and his colleagues in the Immunobiology and Transplant Science Center at the Houston Methodist Research Institute, the team discovered an interaction between two molecules that can be manipulated to potentially solve this problem. “If we can do this and develop better and more specific drugs to selectively stop super-enhancers, asthmatic patients may never have to struggle for air again,” he said.

The inner lining of lung airways is made up of epithelial cells that allow air to travel in and out, and this inner lining keeps the airways open, Li notes. “Embedded in these epithelial cells are a very important cell type called mucin-producing cells that are vital for keeping the epithelial surface moisturized and healthy, and they secrete mucin to protect the surface of the airways. Production of mucin is normally tightly controlled, but too much of it can be damaging,” he said.

Central to their findings was the identification of T helper cells that communicate with mucin-producing cells in the lungs through a small protein called interleukin 9 (IL-9). These T helper cells are a specialized type of white blood cells responsible for helping other cells in the immune system recognize foreign toxins by secreting IL-9 to regulate immune responses.  

In asthma, the T helper cells in the lungs are hyperactive and express a molecule called OX40. To help immune cells survive, OX40 organizes super-enhancers, which are regions of DNA that control what genes become active, causing T helper cells to produce an abundance of IL-9. This, in turn, leads to massive production of mucin in the airways, eventually clogging them up.   

“We were able to decipher how such great quantities of IL-9 are produced by T helper cells,” Li said. “In essence, OX40 activates the IL-9 gene in T helper cells, leading to the overproduction of IL-9 through a powerful molecular machinery of super-enhancers that regulate gene expression.”  

Using chemical inhibitors, Li and his colleagues found a new way to stop this assembly of IL-9 gene super-enhancers to prevent the production of IL-9. This may point to new ways of treating asthma.

“Finding new approaches to target and block super-enhancers may provide a new means of treatment for asthma patients that is likely to be more efficacious than the standard of care, which is now steroids,” Li said.

 

Text provided by Houston Methodist. To speak with Xian C. Li, Ph.D., contact Lisa Merkl, Houston Methodist, at 281-620-2502 or lmerkl@houstonmethodist.org. For more information about Houston Methodist, visit houstonmethodist.org. Follow us on Twitter and Facebook.

 

-----------------------

For more information: Guidance of super-enhancers in regulation of IL-9 induction and airway inflammation. Journal of Experimental Medicine DOI: http://dx.doi.org/10.1084/jem.20170928 (Feb. 5, 2018) X. Xiao, Y. Fan, J. Li, X. Zhang, X. Lou, Y. Dou, X. Shi, P. Lan, Y. Xiao, L. Minze and X.C. Li.

 

###

About the Journal of Experimental Medicine The Journal of Experimental Medicine (JEM) features peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions are made by research-active scientists in conjunction with in-house scientific editors. JEM provides free online access to many article types from the date of publication and to all archival content. Established in 1896, JEM is published by Rockefeller University Press. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.


Comment/Share





Chat now!